Á lódáil...
Benefit assessment in Germany: implications for price discounts
BACKGROUND: The AMNOG regulation, introduced in 2011 in Germany, changed the game for new drugs. Now, the industry is required to submit a dossier to the GBA (the central decision body in the German sickness fund system) to show additional benefit. After granting the magnitude of the additional bene...
Na minha lista:
| Foilsithe in: | Health Econ Rev |
|---|---|
| Main Authors: | , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
Springer Berlin Heidelberg
2016
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4970987/ https://ncbi.nlm.nih.gov/pubmed/27485438 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13561-016-0109-3 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|